TY - JOUR
T1 - Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients
AU - Sticchi, Laura
AU - Di Biagio, Antonio
AU - Sartini, Marina
AU - Rappazzo, Emanuela
AU - Nicolini, Laura A.
AU - Cenderello, Giovanni
AU - Valle, Caterina
AU - Azzola, Emilio
AU - Grasso, Alessandro
AU - De Leo, Pasqualina
AU - Boldrini, Alessandra
AU - Setti, Maurizio
AU - Prinapori, Roberta
AU - Lorusso, Carolina
AU - Bruzzone, Bianca
AU - Icardi, Giancarlo
AU - Alessandrini, Anna I.
AU - Bartolacci, Valentina
AU - Boni, Silvia
AU - Coppelli, Martina
AU - Dentone, Chiara
AU - Mazzarello, Giovanni
AU - Viscoli, Claudio
PY - 2015/10/1
Y1 - 2015/10/1
N2 - We describe the genotypes and allele distribution of interleukin 28B (IL28B) rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) in hepatitis C virus (HCV) G1-4 infected patients, to assess predictive ability and to determine whether the combined determination of two IL28B SNPs might improve sustained virologic response (SVR) prediction of both in HCV mono- and HIV/HCV co-infected patients. IL28B SNPs were genotyped in 269 patients, 181 mono- and 88 co-infected, treated with pegylated interferon and ribavirin. Data stratified by HCV mono- and HCV/HIV co-infected patients showed that 58% and 31% of the rs12979860CC carriers and 49% and 21% of the rs8099917TT carriers had SVR. IL28B SNPs, HCV mono-infection and HCV RNA load were associated with SVR as independent predictors in the two study groups as a whole. ROC curve analyses in the two populations separately, based on gender, age, baseline HCV RNA load and rs12979860/rs8099917 revealed similar receiver operating characteristics (ROC) areas under the curve values. Combining the determination of IL28B SNPs, rs8099917 genotyping improved the response prediction in rs12979860CT carriers only in mono-infected patients. In the era of direct-acting antiviral agents, adopting SVR baseline predictors to orientate naive-patient management represents an important issue. A model involving IL28B SNPs appears able to predict SVR in both populations.
AB - We describe the genotypes and allele distribution of interleukin 28B (IL28B) rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) in hepatitis C virus (HCV) G1-4 infected patients, to assess predictive ability and to determine whether the combined determination of two IL28B SNPs might improve sustained virologic response (SVR) prediction of both in HCV mono- and HIV/HCV co-infected patients. IL28B SNPs were genotyped in 269 patients, 181 mono- and 88 co-infected, treated with pegylated interferon and ribavirin. Data stratified by HCV mono- and HCV/HIV co-infected patients showed that 58% and 31% of the rs12979860CC carriers and 49% and 21% of the rs8099917TT carriers had SVR. IL28B SNPs, HCV mono-infection and HCV RNA load were associated with SVR as independent predictors in the two study groups as a whole. ROC curve analyses in the two populations separately, based on gender, age, baseline HCV RNA load and rs12979860/rs8099917 revealed similar receiver operating characteristics (ROC) areas under the curve values. Combining the determination of IL28B SNPs, rs8099917 genotyping improved the response prediction in rs12979860CT carriers only in mono-infected patients. In the era of direct-acting antiviral agents, adopting SVR baseline predictors to orientate naive-patient management represents an important issue. A model involving IL28B SNPs appears able to predict SVR in both populations.
KW - Hepatitis C virus-G1
KW - Hepatitis C virus-G4
KW - Human immunodeficiency virus
KW - Interleukin-28B rs12979860
KW - Interleukin-28B rs8099917
UR - http://www.scopus.com/inward/record.url?scp=84947937934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947937934&partnerID=8YFLogxK
M3 - Article
C2 - 26485009
AN - SCOPUS:84947937934
VL - 38
SP - 499
EP - 509
JO - New Microbiologica
JF - New Microbiologica
SN - 1121-7138
IS - 4
ER -